home / stock / dyai / dyai news

DYAI News and Press, Dyadic International Inc. From 03/28/24

Stock Information
Company Name: Dyadic International Inc.
Stock Symbol: DYAI
Market: OTC
Website: dyadic.com
Menu
DYAI DYAI Quote DYAI Short DYAI News DYAI Articles DYAI Message Board
Get DYAI Alerts

News, Short Squeeze, Breakout and More Instantly...
DYAI - Dyadic International GAAP EPS of -$0.24 misses by $0.01, revenue of $2.9M misses by $0.15M

2024-03-28 16:03:21 ET More on Dyadic International Dyadic's Michael Tarnok to step down as Chairman of the board of directors Dyadic announces strategic partnership agreement to develop rabies vaccines Seeking Alpha’s Quant Rating on Dyadic International...
DYAI - Dyadic's Michael Tarnok to step down as Chairman of the board of directors

2024-03-28 08:58:20 ET More on Dyadic International Dyadic announces strategic partnership agreement to develop rabies vaccines Seeking Alpha’s Quant Rating on Dyadic International Historical earnings data for Dyadic International Financial inform...

DYAI - Dyadic Announces Change in Board and Management Leadership Roles

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins f...

DYAI - Expected US Company Earnings on Thursday, March 28th, 2024

Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
DYAI - Dyadic to Attend Industry Events in April

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction an...

DYAI - Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic&...

DYAI - Dyadic to Attend Future Food Tech Event March 21 - 22, 2024 in San Francisco, California

JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction an...
DYAI - Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein productio...

DYAI - CORRECTION - Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release follows: JUPITER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic Inte...

DYAI - Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing it...
Previous 10 Next 10